The main reasons for the recommendations by the independent data monitoring committee to terminate this study early and develop future combinations as earlier treatment lines were the (1) lack of durable response to TAS-117 in heavily treated patients with diverse cancer types who were refractory to standard treatments and (2) low accrual rate attributed to the low frequency of PI3K/Akt gene aberrations. This evidence concerns the gene PIK3CA and cancer.